
|Articles|December 18, 2013
- Melanoma (Issue 1)
- Volume 1
- Issue 1
The Outlook for BRAF Inhibitors in Melanoma
Author(s)Antoni Ribas, MD, PhD
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the outlook for BRAF inhibitors in melanoma.
Advertisement
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the outlook for BRAF inhibitors in melanoma.
Read more about BRAF inhibitors for the treatment of melanoma and
Articles in this issue
about 12 years ago
Two BRAF Fusions Discovered in Some Pan-Negative Melanomasabout 12 years ago
Understanding the Biologic Pathways in Basal Cell Carcinomaabout 12 years ago
Advances in Metastatic Melanomaabout 12 years ago
Targeted Therapies in Basal Cell Carcinomaabout 12 years ago
The Treatment of Melanoma With Emerging Targeted TherapiesAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















